+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018

  • ID: 4614621
  • Clinical Trials
  • June 2018
  • Region: Global
  • 982 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Amgen Inc
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Co
  • Eisai Co Ltd
  • F. Hoffmann-La Roche Ltd
  • MORE
Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018

Summary

The author's clinical trial report, “Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018" provides an overview of Renal Cell Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Renal Cell Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using the author's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Amgen Inc
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Co
  • Eisai Co Ltd
  • F. Hoffmann-La Roche Ltd
  • MORE
Report Guidance
Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Renal Cell Carcinoma to Oncology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Renal Cell Carcinoma to Oncology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Renal Cell Carcinoma Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Renal Cell Carcinoma
Jun 20, 2018: SillaJen enrols first patient in REN026 trial
Jun 13, 2018: TRACON Announces Presentation Of Preclinical Data From Studies Of TRC105 In Combination With A PD-1 Antibody In Murine Models Of Colorectal Cancer
Jun 12, 2018: Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930
Jun 11, 2018: Arcus Biosciences Announces FDA Clearance of INDs for AB928 and AB122 and Initiation of Phase 1/1b Program to Evaluate AB928 Combinations
Jun 03, 2018: Merck's KEYTRUDA (pembrolizumab) Showed Overall Response Rate of Nearly 40 Percent as First-Line Therapy in Patients with Advanced Clear Cell Renal Cell Carcinoma (RCC) in Phase 2 KEYNOTE-427 Study
Jun 03, 2018: Eisai and Merck Announce Data at 2018 ASCO Annual Meeting from Investigational Studies of LENVIMA (lenvatinib) and KEYTRUDA (pembrolizumab) Combination Therapy in Four Different Tumor Types
Jun 03, 2018: Phase III Trial Finds Many People With Advanced Kidney Cancer Do Not Need Surgery
Jun 01, 2018: Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimumab) Provided Significant and Sustained Health-Related Quality of Life Improvements in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma in CheckMate -214 Study
May 17, 2018: Eisai to Present Data on Oncology Pipeline and Products at 54th ASCO Annual Meeting
May 16, 2018: New Data from Merck's Leading Immuno-Oncology Clinical Development Program in Over 25 Tumor Types to Be Presented at 2018 ASCO Annual Meeting
May 08, 2018: X4 Pharmaceuticals to Present Clinical Data from Pilot Study of Combination of X4P-001-IO and Opdivo (nivolumab)
May 04, 2018: CStone announces first patient dosed with anti-CTLA-4 antibody CS1002 of a Phase I study in Australia
Apr 26, 2018: Cabozantinib to Be Featured in 15 Presentations at ASCO 2018 Annual Meeting
Apr 12, 2018: GamaMabs Pharma to Present New Data on Expression of Anti-Müllerian Hormone type II Receptor in Non-gynecological Cancers and on First ADC Candidate Targeting AMHRII
Apr 10, 2018: Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About
Contact
Disclaimer
Source

List of Tables
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Region, 2018*
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
Renal Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018*
Renal Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2018*
Renal Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries, 2018*
Renal Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018*
Renal Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018*
Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2018*
Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2018*
Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase, 2018*
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase 2018*
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2018*
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2018*
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
Renal Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018*
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*

List of Figures
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Region (%), 2018*
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
Renal Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018*
Renal Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018*
Renal Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries (%), 2018*
Renal Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018*
Renal Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018*
Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2018*
Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2018*
Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase (%), 2018*
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2018*
Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2018*
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2018*
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
Renal Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018*
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Pfizer Inc
  • Novartis AG
  • Bayer AG
  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Merck & Co Inc
  • AstraZeneca Plc
  • Amgen Inc
  • Eisai Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll